Phase-appropriate analytical method development

Phase-appropriate analytical method development


Drug development requires an average overall investment of USD 1.5 – 4.5 billion and remains at high risk due to the huge attrition rate phase after phase. The pre-clinical development phase and the phase 1 clinical trial show the highest attrition rate due to toxicity or drug metabolism and pharmacokinetic issues. Mitigating the risk during a new drug candidate development program starting from the discovery phase onwards remains essential for drug development efficiency and success.

The challenge is to perform the necessary steps in a structured and predictive manner which is also tailored to the project at hand. This can be achieved by committing the resources to stage-appropriate steps and confirming their suitability for the following steps.

This structured and stepwise project plan reduces the level of investments into future work prior to receiving positive results from the earlier stage which would justify such investments.

Interested in reading the full resource?

Please fill out the form to unlock the rest of the content.

Latest Resources

Our team members share deep, scientific understanding and insights into their respective fields of expertise.

Want to hear more from Ardena?

Sign up to receive drug development insights, the latest on industry trends & Ardena news.

Stay up to date with our latest news and announcements.
Get deep, scientific understanding and insights into our key fields of expertise.
See the events we're attending and register for webinars we're hosting.